Andere Sprachen OptiNose, Inc.

Aktien

A2H5PR

US68404V1008

OPTN

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:07:41 30.04.2024			% 5 Tage	% 1. Jan.
0,817 ^USD	-4,91 %		-15,46 %	-36,58 %

25.04.	OptiNose, Inc. gibt eine Umsatzprognose für das erste Quartal 2024 ab	CI
25.04.	Transcript : OptiNose, Inc. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25.04.
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	25.04.
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25.04.
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	25.04.
Optinose to Present at the Needham Virtual Healthcare Conference	04.04.
Sector Update: Health Care Stocks Steady Premarket Monday	18.03.
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	15.03.
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	15.03.
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	15.03.
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	15.03.
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	14.03.
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	14.03.
OptiNose: Q4 Earnings Snapshot	07.03.
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	07.03.
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	07.03.
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	07.03.
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
North American Morning Briefing : Powell Still in -2-	07.03.
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	29.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen OptiNose, Inc.

Aktien

A2H5PR

US68404V1008

OPTN

Andere Sprachen

Filter